Finch Therapeutics Group, Inc.
FNCHQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.38M
Close$
Share Statistics
| Market cap | $16.38 Million |
|---|---|
| Enterprise Value | $29.33 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -99.63% |
|---|---|
| Return on Assets | -31.08% |
| Return on Invested Capital | -48.13% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 10.31 |
| Enterprise Value to EBIT | -1.48 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.99 |
| Debt to Equity | 2.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-8.40
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-30.00
Average shareholder expectationRevenue Estimate
$3.60 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Finch Therapeutics Group Inc
131 employees
CEO: Matthew Blischak Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and ta...